143 related articles for article (PubMed ID: 33676835)
21. Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations.
Das A; Alshareef M; Martinez Santos JL; Porto GBF; McDonald DG; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2020 Nov; 22(11):2017-2025. PubMed ID: 32253706
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
24. Expression and roles of system L amino acid transporters in human embryonal carcinoma cells.
Chatsirisupachai K; Kitdumrongthum S; Panvongsa W; Janpipatkul K; Worakitchanon W; Lertjintanakit S; Wongtrakoongate P; Chairoungdua A
Andrology; 2020 Nov; 8(6):1844-1858. PubMed ID: 32741077
[TBL] [Abstract][Full Text] [Related]
25. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
[TBL] [Abstract][Full Text] [Related]
26. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.
Dosil MA; Mirantes C; Eritja N; Felip I; Navaridas R; Gatius S; Santacana M; Colàs E; Moiola C; Schoenenberger JA; Encinas M; Garí E; Matias-Guiu X; Dolcet X
J Pathol; 2017 Jun; 242(2):152-164. PubMed ID: 28349562
[TBL] [Abstract][Full Text] [Related]
27. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.
Noel EE; Yeste-Velasco M; Mao X; Perry J; Kudahetti SC; Li NF; Sharp S; Chaplin T; Xue L; McIntyre A; Shan L; Powles T; Oliver RT; Young BD; Shipley J; Berney DM; Joel SP; Lu YJ
Am J Pathol; 2010 Jun; 176(6):2607-15. PubMed ID: 20395447
[TBL] [Abstract][Full Text] [Related]
28. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
29. Novel sequential therapy with metformin enhances the effects of cisplatin in testicular germ cell tumours via YAP1 signalling.
He K; Li Z; Ye K; Zhou Y; Yan M; Qi H; Hu H; Dai Y; Tang Y
Cancer Cell Int; 2022 Mar; 22(1):113. PubMed ID: 35264157
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
[TBL] [Abstract][Full Text] [Related]
31. Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours.
Harpelunde Poulsen K; Nielsen JE; Grønkær Toft B; Joensen UN; Rasmussen LJ; Blomberg Jensen M; Mitchell RT; Juul A; Rajpert-De Meyts E; Jørgensen A
BMC Cancer; 2020 Apr; 20(1):349. PubMed ID: 32326899
[TBL] [Abstract][Full Text] [Related]
32. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
[TBL] [Abstract][Full Text] [Related]
33. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
36. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Vaughn DJ; Hwang WT; Lal P; Rosen MA; Gallagher M; O'Dwyer PJ
Cancer; 2015 May; 121(9):1463-8. PubMed ID: 25522918
[TBL] [Abstract][Full Text] [Related]
38. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
39. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
40. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
